Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model

Award Number: SB1AR066439
ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/08/2015
PERIOD OF PERFORMANCE END DATE: 07/31/2026

Group Awards By:

View Award Description

Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model - Abstract Osteoarthritis (OA) is a leading cause of disability in the developed world, affecting over 30 million adults in the US with an economic burden of over $486 billion per year. Advanced OA is most commonly treated with total joint replacement, but this is suboptimal for younger patients, especially those under 55 who lead an active lifestyle, because of the high occurrence of multiple revision surgeries. For this growing patient population, Cytex is developing implants pairing a patented 3D weaving technology with additive manufacturing to facilitate cartilage and bone regeneration in the joint. The implant is designed to support joint loading immediately at the time of implantation and to allow integration and development of osteochondral tissue. Both an acellular implant and a tissue engineered implant that combines the acellular scaffold with autologous cells have demonstrated in large animal models of OA the capability of repairing osteochondral lesions and restoring pain-free joint function for extended durations. The tissue engineered implant is particularly desirable for patients without a potent endogenous cell source to repopulate the acellular implant and synthesize a mature extracellular matrix in vivo. Cytex has chosen femoroacetabular impingement (FAI) in the hip as a lead indication for a pilot clinical study with the acellular implant. FAI presents in active, young patients, with no good option to repair the resulting osteochondral lesions, which progress into more severe OA. The tissue engineered implant will follow the acellular product into clinical study. Autologous cells, as used in our pre- clinical studies, require time-consuming cell isolation and expansion steps. Instead, Cytex will use allogeneic mesenchymal stem cells (MSCs) derived from bone marrow, which express very low levels of major histocompatibility complex (MHC) class I and class II antigens. To prepare the allogeneic tissue engineered implants for clinical study, Cytex must further develop the tissue engineered implant to overcome specific commercialization hurdles. The goal of this proposal is to address these hurdles: 1) Cytex must identify and develop potency assays that measure the biological activity of the seeded cells and set acceptance criteria for those assays. 2) Cytex will identify cryopreservation and storage conditions for the implants to be available off- the-shelf because surgeons and patients are unlikely to wait several weeks for an implant to be made-to-order. 3) manufacturing of the tissue engineered implants will be transferred to a contract manufacturer that follows the current good manufacturing practices (cGMPs) required for regulatory approval. 4) Cytex, with an experienced regulatory consulting firm, will engage with the US FDA to discuss requirements for clinical study approval. The culmination of this project will be an off-the-shelf tissue engineered implant for cartilage repair that will enable Cytex to broaden its implant portfolio and enable treatment for patients that currently have no good clinical options either because of their advanced age or disease state.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	CYTEX THERAPEUTICS INC	2609 N DUKE ST STE 303A	DURHAM	NC	27704	DURHAM	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	6	7/29/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $399,998 )
2024	2024	CYTEX THERAPEUTICS INC	2609 N DUKE ST STE 303A	DURHAM	NC	27704	DURHAM	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	6	7/31/2024	NON-COMPETING CONTINUATION	$399,998
														Subtotal = $399,998

Issue Date FY: 2023 ( Subtotal = $399,998 )
2023	2023	CYTEX THERAPEUTICS, INC.	2609 N DUKE ST STE 303A	DURHAM	NC	27704	DURHAM	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	5	8/3/2023	NON-COMPETING CONTINUATION	$399,998
														Subtotal = $399,998

Issue Date FY: 2022 ( Subtotal = $400,000 )
2022	2022	CYTEX THERAPEUTICS, INC.	2609 N DUKE ST STE 303A	DURHAM	NC	27704	DURHAM	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	4	9/20/2022	COMPETING CONTINUATION	$400,000
														Subtotal = $400,000

Grand Total All Awards = $1,199,996

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model

Award Number: SB1AR066439

ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/08/2015

PERIOD OF PERFORMANCE END DATE: 07/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer